UQ-CSL V451 / University of Queensland, CSL Behring - LARVOL DELTA

Australia halts local COVID-19 vaccine development due to false HIV positives (Reuters) - "Antibodies generated by the vaccine being developed by the University of Queensland (UQ) and biotech firm CSL...were found to lead to some false positive HIV test results...CSL and the Australian government had together decided to stop Phase 2 and Phase 3 trials. CSL...will instead produce an extra 20 million doses of the Oxford vaccine...The government said it has also secured additional doses of Novavax vaccines. Australia also has a contract for 10 million doses of a vaccine being developed by Pfizer, with regulatory approval expected by January 2021....The country is scheduled to start vaccinations in March 2021 and expects to inoculate its whole population by the end of the year."

Commercial • Non-US regulatory • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Australian COVID-19 vaccine candidate produces antibody response in early tests (indianexpress) - P1, N=NA; "Early testing of a potential COVID-19 vaccine developed by an Australian university and CSL Ltd has shown it to be safe and produce an antibody response, Minister for Health Greg Hunt said on Friday....'It is doing its job. That is particularly so in the elderly, and that is an especially important outcome'....Should it pass those trials, Hunt said it could be ready for distribution by the third quarter of 2021."

Commercial • P1 data • Infectious Disease • Novel Coronavirus Disease

Australia expects to receive first Covid-19 vaccine by early next year (Capital) - "The Australian government has made a deal with CSL Ltd to manufacture two vaccines. One agreement is signed between CSL and AstraZeneca for the expected manufacture of the Oxford University vaccine candidate AZD1222. This is scheduled to be released in Australia early next year. Approximately 30 million doses of this vaccine will be manufactured....The second deal is with CSL and the University of Queensland where it will produce a Covid-19 vaccine called UQ-CSL V451. It is due to begin second stage clinical trials late this year, which means it would supply 51 million doses of it by mid-2021. If both vaccines pass clinical trials, Australia is said to spend A$1.7bn ($1.24bn, £930m, €1.03bn) for nearly 85m doses."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease